2.5 Antiarrhythmic Drugs: Amiodarone & Lidocaine in Refractory VF/pVT

2.5 Antiarrhythmic Drugs: Amiodarone & Lidocaine in Refractory VF/pVT

In the management of adult cardiac arrest, shockable rhythms such as ventricular fibrillation (VF) and pulseless ventricular tachycardia (pVT) are the most treatable underlying electrical disturbances. The primary, most effective intervention for these rhythms is immediate, high-quality cardiopulmonary resuscitation (CPR) combined with rapid defibrillation. However, in a significant subset of patients, these malignant arrhythmias persist or recur despite multiple defibrillation attempts and the administration of a vasopressor (typically epinephrine). This state is known as refractory VF/pVT. When the rhythm remains shockable after at least three properly delivered shocks, the Advanced Cardiovascular Life Support (ACLS) guidelines indicate the administration of antiarrhythmic medications.

The overarching goal of introducing an antiarrhythmic at this juncture is to stabilize the myocardial cell membrane, raise the fibrillation threshold, and make subsequent shocks more likely to successfully convert the rhythm to an organized, perfusing one. The AHA guidelines recognize two primary antiarrhythmic agents for this purpose: amiodarone and lidocaine. Both have been shown to improve the rates of survival to hospital admission, although neither has definitively proven to increase the rate of survival to hospital discharge with favorable neurologic intactness in large randomized controlled trials.

Amiodarone: Mechanism of Action and Clinical Application

Amiodarone is a highly complex, iodine-rich antiarrhythmic medication that exhibits properties of all four Vaughn-Williams antiarrhythmic classes. Although primarily classified as a Class III agent—meaning it primarily works by blocking potassium channels to prolong the cardiac action potential and the effective refractory period—it also demonstrates sodium channel blockade (Class I), non-competitive beta-adrenergic antagonism (Class II), and calcium channel blockade (Class IV). This broad spectrum of electrophysiological effects decreases the excitability of myocardial tissue and interrupts the reentrant circuits that perpetuate VF and pVT.

During a cardiac arrest, the pharmacokinetics of amiodarone are influenced by the profound low-flow state of CPR. The recommended dosing protocol reflects the need to rapidly achieve therapeutic myocardial concentrations:

• First Dose: 300 mg administered via a rapid intravenous (IV) or intraosseous (IO) bolus. It is crucial to flush the line immediately with 20 mL of normal saline and, if given peripherally, to elevate the extremity to facilitate transit to the central circulation.
• Second Dose: If VF or pVT persists after another two-minute cycle of CPR and a subsequent rhythm check/shock, a second dose of 150 mg IV/IO may be administered.

Providers must be acutely aware of amiodarone's formulation. Standard amiodarone is dissolved in polysorbate 80 and benzyl alcohol, which are vasoactive solvents that can cause significant hypotension and vasodilation. While this is less of an immediate concern during active cardiac arrest when blood pressure is artificially maintained by chest compressions, it becomes a critical issue if the patient achieves return of spontaneous circulation (ROSC). A precipitous drop in blood pressure post-ROSC may necessitate the immediate initiation of vasopressor infusions.

Lidocaine: Mechanism of Action and Clinical Application

Lidocaine is a Class Ib antiarrhythmic agent. Its mechanism of action is much narrower than that of amiodarone. Lidocaine specifically blocks fast voltage-gated sodium channels in the cardiac conduction system, primarily acting on the His-Purkinje system and ventricular myocardium. By doing so, it decreases automaticity, reduces the duration of the action potential, and shortens the effective refractory period. Notably, lidocaine binds preferentially to sodium channels in ischemic and depolarized tissue, making it theoretically ideal for the ischemic environment of a cardiac arrest.

The AHA guidelines position lidocaine as an equally acceptable alternative to amiodarone for the treatment of refractory VF/pVT. The choice between the two is often driven by institutional protocol, medication availability, and provider familiarity.

The dosing protocol for lidocaine is weight-based, which requires a rapid estimation of the patient's lean body mass during the resuscitation:

• First Dose: 1 to 1.5 mg/kg IV/IO. For an average 80 kg adult, this translates to a dose of approximately 80 to 120 mg, typically administered as a rapid push.
• Second Dose: If the shockable rhythm continues, a second dose of 0.5 to 0.75 mg/kg may be administered at a 5-to-10-minute interval.
• Maximum Cumulative Dose: The total administered dose of lidocaine should not exceed 3 mg/kg. Exceeding this limit increases the risk of lidocaine toxicity, which can manifest neurologically (seizures, altered mental status) once ROSC is achieved, as well as cause profound myocardial depression.

Integration into the Cardiac Arrest Algorithm

The administration of antiarrhythmic drugs must be seamlessly integrated into the choreography of the resuscitation effort. It is paramount that preparing and pushing these medications does not lead to interruptions in chest compressions. The sequence proceeds as follows: Shock 1 -> CPR -> Shock 2 -> CPR + Epinephrine -> Shock 3 -> CPR + Antiarrhythmic.

During the two-minute period of CPR following the third shock, the team leader should order the antiarrhythmic. The medication is drawn up, administered as a rapid push, and flushed—all while chest compressions continue. This timing ensures that the drug is circulated through the coronary arteries by the chest compressions, allowing it to reach the myocardium and exert its membrane-stabilizing effects before the rhythm is re-evaluated at the end of the two-minute cycle.

In the post-resuscitation phase, if a patient who received an antiarrhythmic achieves ROSC, prophylactic continuous infusion of the same agent is generally not recommended unless there is recurrent malignant arrhythmia. Providers must monitor the post-arrest 12-lead ECG closely, particularly looking for QT prolongation if amiodarone was used, as this can predispose the patient to Torsades de Pointes.